BioCentury
ARTICLE | Clinical News

Agios announces ASH abstracts, earnings

November 6, 2015 3:27 AM UTC

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) fell $2.63 to $75.25 on Thursday after its earnings report and the release of abstracts for AG-120 and AG-221 in advance of the American Society of Hematology (ASH) meeting in December.

Among 181 evaluable patients in a Phase I/II trial of AG-221 to treat advanced hematological malignancies, 74 (41%) had an objective response, including 54 with relapsed/refractory acute myelogenous leukemia (AML). Median response duration was 6.9 months among all patients and 6 months in relapsed/refractory AML patients. ...